TEL
AVIV, Israel, Feb. 5, 2024
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB)
(Chemomab), a clinical stage biotechnology company focused on the
discovery and development of innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today
announced that CEO Dr. Adi Mor
and other members of its senior management team will participate in
two upcoming investor conferences. Dr. Mor will deliver a corporate
presentation and participate in one-on-one investor meetings
at the Oppenheimer 34th Annual Healthcare Life
Sciences Conference, February 13-14,
2024 (virtual), and the Leerink Partners Global Biopharma
Conference, March 11-13, 2024 in
Miami, Florida. The Oppenheimer
Conference presentation will be webcast live and will be available
on the investor relations section of the Chemomab website for 90
days.
Oppenheimer
34th Annual Healthcare Life Sciences
Conference
|
Date:
|
February 14,
2024
|
Time:
|
8:00 am ET
|
Venue:
|
Virtual
|
Format:
|
Webcast
presentation
|
Webcast Link:
|
https://wsw.com/webcast/oppenheimer33/cmmb/2744734
|
Information:
|
opcoconferences@opco.com
|
Leerink Partners
Global BioPharma Conference
|
Date:
|
March 12,
2024
|
Time:
|
10:40am ET
|
Venue:
|
Fontainebleau
Hotel
|
Format:
|
Live
presentation
|
Information:
|
LeerinkEvents@Leerink.com
|
About Chemomab Therapeutics Ltd.
Chemomab
is a clinical stage biotechnology company developing
innovative therapeutics for fibro-inflammatory
diseases with high unmet need. Based on the unique and
pivotal role of CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal
antibody that neutralizes CCL24 activity. In clinical and
preclinical studies, CM-101 appears safe, with the potential to
treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has
reported positive results from three clinical trials of CM-101 in
patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with
topline data expected midyear 2024. A CM-101 program for the
treatment of systemic sclerosis is Phase 2-ready. For more
information about Chemomab, visit
chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-upcoming-investor-conferences-302052924.html
SOURCE Chemomab Therapeutics, Ltd.